The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Sponsor
Taipei Veterans General Hospital, Taiwan
Study ID
NCT01608841
Phase
PHASE2
Status
Unknown

Conditions

  • Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Erlotinib 100 mg 1# PO qd till disease progression

Study Details

The purpose of this study is to investigate the influence of epidermal growth factor receptor mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.

Key Dates

First listed
May 31, 2012
Start date
Jul 31, 2005
Status verified
Feb 2015
Primary completion
Oct 31, 2015
Completion
Oct 31, 2015

Study Design

Enrollment
88 participants (estimated)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Arms

  • No Intervention: Gemcitabine
  • Experimental: Gemcitabine plus erlotinib

Primary Outcome Measure

disease control rate [ Time Frame: eight weeks ]

Central Contacts

Related Studies